NO20065304L - Vaksiner - Google Patents

Vaksiner

Info

Publication number
NO20065304L
NO20065304L NO20065304A NO20065304A NO20065304L NO 20065304 L NO20065304 L NO 20065304L NO 20065304 A NO20065304 A NO 20065304A NO 20065304 A NO20065304 A NO 20065304A NO 20065304 L NO20065304 L NO 20065304L
Authority
NO
Norway
Prior art keywords
adjuvant
antigen
shigatoxin
complexed
metal salt
Prior art date
Application number
NO20065304A
Other languages
English (en)
Norwegian (no)
Inventor
Patrick Chomez
Catherine Pascaline Collignon
Marcelle Paulette Van Mechelen
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of NO20065304L publication Critical patent/NO20065304L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20065304A 2004-05-21 2006-11-20 Vaksiner NO20065304L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0411411.2A GB0411411D0 (en) 2004-05-21 2004-05-21 Vaccines
PCT/EP2005/005555 WO2005112991A2 (en) 2004-05-21 2005-05-19 Vaccines

Publications (1)

Publication Number Publication Date
NO20065304L true NO20065304L (no) 2006-11-20

Family

ID=32607764

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065304A NO20065304L (no) 2004-05-21 2006-11-20 Vaksiner

Country Status (16)

Country Link
US (1) US20080069832A1 (https=)
EP (1) EP1761275A2 (https=)
JP (1) JP2007538044A (https=)
KR (1) KR20070029730A (https=)
CN (1) CN1956729A (https=)
AU (1) AU2005244615A1 (https=)
BR (1) BRPI0511185A (https=)
CA (1) CA2564778A1 (https=)
GB (1) GB0411411D0 (https=)
IL (1) IL178890A0 (https=)
MA (1) MA28609B1 (https=)
MX (1) MXPA06013386A (https=)
NO (1) NO20065304L (https=)
RU (1) RU2006139424A (https=)
WO (1) WO2005112991A2 (https=)
ZA (1) ZA200609500B (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006104890A2 (en) 2005-03-31 2006-10-05 Glaxosmithkline Biologicals Sa Vaccines against chlamydial infection
DK2457926T3 (da) 2005-04-29 2015-01-05 Glaxosmithkline Biolog Sa Ny fremgangsmåde til forebyggelse eller behandling af M. tuberkulose-infektion
JP2008540625A (ja) * 2005-05-19 2008-11-20 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｅ．ｃｏｌｉ易熱性毒素のＢ−サブユニット、抗原およびアジュバントを含むワクチン組成物
GB0524409D0 (en) * 2005-11-30 2006-01-11 Glaxosmithkline Biolog Sa Vaccines
GB0524408D0 (en) * 2005-11-30 2006-01-11 Glaxosmithkline Biolog Sa Vaccines
JP2009536653A (ja) * 2006-05-09 2009-10-15 ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド Ｈｉｖ−１免疫原性組成物
EP1938836A1 (en) * 2006-12-28 2008-07-02 Universite Rene Descartes (Paris V) Compositions comprising a B subunit of shiga toxin and a means stimulating NKT cells
JP5331105B2 (ja) 2007-05-24 2013-10-30 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 凍結乾燥抗原組成物
GB0724357D0 (en) * 2007-12-14 2008-01-23 Glaxosmithkline Biolog Sa Method for preparing protein conjugates
WO2009126819A1 (en) * 2008-04-09 2009-10-15 Advanced Immune Therapeutics, Inc. Methods for improving the bioactivity of therapeutic ige antibodies for the treatment of disease
AU2009344150B2 (en) * 2009-04-09 2014-10-09 Innavac Pty Ltd Immunogenic composition and uses thereof
JP2012523379A (ja) * 2009-04-09 2012-10-04 ザ ユニバーシティー オブ メルボルン 免疫原性組成物およびその使用
GB0910046D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
GB0910045D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
TW201103980A (en) 2009-07-08 2011-02-01 Abbott Biologicals Bv Viral vaccine and use thereof
DE102009056884B4 (de) 2009-12-03 2021-03-18 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
CN104688687A (zh) 2009-12-03 2015-06-10 诺华股份有限公司 疫苗佐剂制备中的亲水过滤
CL2012001399A1 (es) * 2009-12-03 2013-03-08 Novartis Ag Metodo para fabricar adyuvante para vacuna (emulsion aceite/agua con escualeno, polisorbato 80 y trioleato de sorbitan), que comprende (i) formar primera emulsion en homogenizador desde un contendor a otro para formar segunda emulsion, (ii) y microfluidizar primera emulsion para formar segunda emulsion.
DE102009056883B4 (de) * 2009-12-03 2012-08-16 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
EP2506834B1 (en) * 2009-12-03 2016-03-02 Novartis AG Circulation of components during homogenization and microfluidization of emulsions
EP2618842B1 (en) 2010-09-22 2019-04-24 Ena Therapeutics Pty Ltd Novel immunostimulatory method
CN106822883A (zh) 2010-12-14 2017-06-13 葛兰素史密丝克莱恩生物有限公司 分枝杆菌抗原组合物
CN102161998B (zh) * 2011-01-14 2013-01-09 中国人民解放军军事医学科学院附属医院 基于b7-1-pe40kdel外毒素融合基因的dna疫苗及其用途
GB201106357D0 (en) 2011-04-14 2011-06-01 Pessi Antonello Composition and uses thereof
US20140234424A1 (en) * 2011-07-22 2014-08-21 Glaxosmithkline Biologicals Sa Prame purification
EP2666785A1 (en) 2012-05-23 2013-11-27 Affiris AG Complement component C5a-based vaccine
EP2703483A1 (en) 2012-08-29 2014-03-05 Affiris AG PCSK9 peptide vaccine
JP5931113B2 (ja) * 2014-04-08 2016-06-08 ザ ユニバーシティー オブ メルボルン 免疫原性組成物およびその使用
TW201623329A (zh) 2014-06-30 2016-07-01 亞佛瑞司股份有限公司 針對骨調素截斷變異體的疫苗及單株抗體暨其用途
US10695424B2 (en) 2016-12-07 2020-06-30 Glaxosmithkline Biologicals S.A. Method of making a liposome composition
GB201621686D0 (en) * 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
KR101966346B1 (ko) * 2017-01-13 2019-04-05 전북대학교 산학협력단 시가 독소 Stx2e를 제조하는 방법 및 이를 포함하는 부종병을 예방하기 위한 백신 조성물
KR101987851B1 (ko) 2017-04-28 2019-06-11 한국생명공학연구원 장출혈성대장균 유래의 시가독소 타입 1 B-subunit으로 유도된 노인성 황반변성(AMD) 동물모델 및 이를 이용한 스크리닝 방법
BR112019025104A2 (pt) 2017-05-30 2020-06-23 Glaxosmithkline Biologicals S.A. Método de fabricar um sistema de entrega não viral, sistema de entrega não viral, e, composição
AU2018391325B2 (en) 2017-12-21 2024-07-11 Axelia Oncology Pty Ltd Optimised compounds
CN108992667A (zh) * 2018-08-09 2018-12-14 安徽智飞龙科马生物制药有限公司 一种带状疱疹疫苗及其制备方法、应用
EP3886901A1 (en) * 2018-11-29 2021-10-06 GlaxoSmithKline Biologicals S.A. Methods for manufacturing an adjuvant
EP3669890A1 (en) 2018-12-18 2020-06-24 Croda International PLC Filamentous nanoparticles having vaccine adjuvant effect
MX2021015961A (es) 2019-06-26 2022-03-22 Ena Respiratory Pty Ltd Moleculas novedosas.
EP4021407A1 (en) 2019-08-30 2022-07-06 GlaxoSmithKline Biologicals S.A. Jet mixing lipid nanoparticle manufacturing process
CN111333734B (zh) * 2020-03-31 2022-05-03 中国人民解放军军事科学院军事医学研究院 一种百日咳丝状血凝素融合蛋白及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2138997C (en) * 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
CA2218601A1 (en) * 1995-03-24 1996-10-03 Ophidian Pharmaceuticals, Inc. Treatment for verotoxin-producing escherichia coli
GB9711990D0 (en) * 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
EP1078007B1 (en) * 1998-05-15 2005-11-23 Institut Curie Verotoxin b subunit for immunization
PT1187629E (pt) * 1999-04-19 2005-02-28 Glaxosmithkline Biolog Sa Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
EP1229045A1 (en) * 2001-02-01 2002-08-07 Institut Curie Universal carrier for targeting molecules to Gb3 receptor expressing cells

Also Published As

Publication number Publication date
CN1956729A (zh) 2007-05-02
MXPA06013386A (es) 2007-01-23
IL178890A0 (en) 2007-03-08
AU2005244615A1 (en) 2005-12-01
RU2006139424A (ru) 2008-06-27
MA28609B1 (fr) 2007-05-02
KR20070029730A (ko) 2007-03-14
ZA200609500B (en) 2008-02-27
WO2005112991A2 (en) 2005-12-01
US20080069832A1 (en) 2008-03-20
EP1761275A2 (en) 2007-03-14
JP2007538044A (ja) 2007-12-27
BRPI0511185A (pt) 2007-12-04
WO2005112991A3 (en) 2006-03-30
GB0411411D0 (en) 2004-06-23
CA2564778A1 (en) 2005-12-01

Similar Documents

Publication Publication Date Title
NO20065304L (no) Vaksiner
CN111757878A (zh) 一种哒嗪类衍生物抑制剂、其制备方法和应用
ATE426412T1 (de) Adjuvante influenza-vakzine
WO2006032475A3 (en) Staphylococcal immunogenic compositions
DK1898948T3 (da) Polyriboinosinsyre-polyribocytidylsyre-baseret adjuvans
EP1326633A4 (en) COMPOSITION WITH IMMUNOGENIC MICROPARTICLES
CY1112572T1 (el) Εμβολια γριπης που περιλαμβανουν συνδυασμους σωματιδιακων ανοσοενισχυτικων και ανοσοδιεγερτες
NZ621834A (en) Novel adjuvant compositions
NO20075727L (no) Vaksineblanding omfattende B-subenhet av et E.coli varmetoksin og et antigen og en adjuvans
CN114650845A (zh) 抗密蛋白抗体药物偶联物及其医药用途
JP2003530473A5 (https=)
WO2007067681A3 (en) Immunostimulatory compositions and methods
ATE489968T1 (de) Proteosom-liposaccharid-vakzine-adjuvans
JP2007538044A5 (https=)
CN111315744A (zh) 杂芳基并四氢吡啶类化合物、其制备方法、药物组合物及应用
DK1471936T3 (da) HIV-Vaccine og fremgangsmåde til anvendelse
WO2005028496A3 (en) Vaccine for treatment and prevention of herpes simplex virus infection
WO2007002470A3 (en) Inactivated chimeric vaccines and related methods of use
ATE513561T1 (de) Veränderung des th1/th2-gleichgewichts in spalt- grippeimpfstoffen mit adjuvantien
CY1116135T1 (el) Εμβολιο ροταϊου που διεγειρει ετεροτυπικη εγκαρσια προστασια
ATE557099T1 (de) Hpv cd8+ t-zell-epitope
WO2006007555A3 (en) Rotavirus antigens
WO2005009397A3 (en) Human lymphocyte vaccine adjuvant
BRPI0414073A (pt) método para induzir uma resposta imune contra infecção por rotavìrus a partir de um sorotipo de rotavìrus, e, uso de uma cepa de rotavìrus atenuado de um sorotipo
WO2004097000A3 (en) Ligand-exchange functional antigens, and use of same in pharmaceutical vaccine compositions

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application